How to Help Your Patients Save Money on Olumiant: A Provider's Guide to Savings Programs

Olumiant (baricitinib) is one of the most expensive specialty medications on the market — approximately $2,500 to $3,000 per month at list price, with no generic available in the United States as of 2026. For rheumatologists, dermatologists, and other prescribers, understanding and proactively communicating available savings programs can mean the difference between a patient who adheres to therapy and one who abandons it due to cost. This guide covers every resource available to help your patients afford Olumiant.

The Cost Reality: Why Your Patients May Struggle to Pay

Eli Lilly's wholesale acquisition cost (WAC) for Olumiant 2 mg is approximately $2,767 for a 30-day supply; the 4 mg formulation approaches $5,535 for 30 tablets. Even with commercial insurance, patients face:

Specialty tier copays of $100–$500+ per month before any savings programs

Coinsurance of 20–30% on some plans, equaling $500–$900/month before meeting out-of-pocket maximums

Annual PA renewal costs — if a patient's PA lapses, they face out-of-pocket costs while the renewal is processed

Uninsured patients facing the full $2,500–$3,000/month list price without assistance

Program 1: Olumiant Together Savings Card (Commercially Insured Patients)

For commercially insured patients, the Olumiant Together savings card is the highest-value cost reduction tool available. Key details for providers:

Patient out-of-pocket: As low as $5/month with commercial insurance coverage; as low as $25/month for commercially insured patients without coverage

Annual maximum savings: Up to $10,600 per calendar year (good through 12/31/2028 or 24 months after first use, whichever comes first)

Eligibility: Commercially insured patients ONLY — not available for Medicare, Medicaid, TRICARE, or other government-funded programs

Enrollment: olumiant.com/savings or call 1-844-658-6426. Your practice can help patients enroll during or immediately after their visit.

Clinical recommendation: Consider adding savings card enrollment to your new Olumiant start workflow, alongside TB screening orders and baseline lab work. Enrolling at the time of prescribing removes a friction point that can delay or prevent therapy initiation.

Program 2: Lilly Cares Foundation (Uninsured and Underinsured Patients)

For patients who are uninsured or underinsured and meet income guidelines, the Lilly Cares Foundation provides Olumiant at no cost. Provider-relevant details:

Patient cost: $0

Eligibility: Uninsured or underinsured patients meeting income requirements. Most people without insurance with limited incomes qualify.

Authorization period: One year, renewable

How to apply: Provider fills out a portion of the application; patient provides proof of income. Apply at lillycares.com or call 1-800-545-6962.

Program 3: Olumiant Together Patient Support (All Patients)

The Olumiant Together program (separate from the savings card) provides comprehensive support services for all patients starting Olumiant, including:

Insurance verification and prior authorization support — they have payer-specific experience and can often accelerate PA timelines

Specialty pharmacy coordination — they work with the patient's insurance to identify the correct in-network specialty pharmacy

Bridge medication support — may be able to provide samples or bridge access while PA is pending

Call 1-844-658-6426 or visit olumiant.com to enroll a patient

Strategies for Medicare Patients

Medicare patients cannot use the Olumiant Savings Card (federal law prohibits manufacturer copay assistance for government program beneficiaries). However, the following strategies can help:

Medicare Extra Help (Low Income Subsidy): Eligible patients may qualify for federal extra help with Part D drug costs — check ssa.gov/extrahelp

State pharmaceutical assistance programs (SPAPs): Many states offer additional help for seniors with high medication costs

Lilly Cares Foundation: Eligible Medicare patients who also qualify based on income may receive Olumiant through Lilly Cares

Medicare Prescription Payment Plan (available since January 2025): Allows patients to spread annual Part D out-of-pocket costs across monthly payments — doesn't reduce total cost but prevents large lump-sum payments

When Insurance Denies Coverage: Appeal Strategies

When a PA is denied, a provider-supported appeal significantly increases the chance of reversal. Effective appeal components include:

A detailed letter of medical necessity explaining why the patient requires baricitinib specifically and why alternatives are not appropriate

Documentation of all prior therapy failures with dates, doses, and documented adverse effects or intolerance

Disease activity scores (DAS28 for RA, SALT score for AA) documenting moderate-to-severe disease

Request for peer-to-peer review if initial appeal is denied — direct physician-to-reviewer conversations have high reversal rates

Integrating Savings Support Into Your Practice Workflow

The most successful practices have a defined workflow for specialty medication cost navigation. A practical framework:

At prescribing visit: Confirm insurance type (commercial vs. Medicare/Medicaid vs. uninsured). Route to appropriate savings program immediately.

Submit PA and enroll in Olumiant Together on the same day as the prescribing visit.

Follow up on PA status within 5 business days. If denied, initiate appeal with letter of medical necessity.

Set annual PA renewal reminders — lapses create unnecessary access gaps for patients.

How medfinder Supports Pharmacy Access for Your Patients

Even when savings programs are in place, patients sometimes can't locate a specialty pharmacy with their specific Olumiant dose in stock. medfinder for providers addresses this gap by calling pharmacies in the patient's area to identify available stock — saving your staff time and ensuring patients don't go without medication. For more, read our full provider access guide: How to help your patients find Olumiant in stock.